Drug Price Trends for KERENDIA

Average Pharmacy Cost for KERENDIA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
KERENDIA 40 MG TABLET	50419-0542-01	22.86037	EACH	2026-02-18
KERENDIA 40 MG TABLET	50419-0542-02	22.86037	EACH	2026-02-18
KERENDIA 40 MG TABLET	50419-0542-06	22.86037	EACH	2026-02-18
KERENDIA 10 MG TABLET	50419-0540-06	22.87377	EACH	2026-01-21

KERENDIA (Finerenone) Market Analysis and Price Projections

Last updated: February 19, 2026

Executive Summary

KERENDIA (finerenone), developed by Bayer, targets chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The drug's mechanism of action, inhibiting the mineralocorticoid receptor (MR) to reduce inflammation and fibrosis, positions it to address a significant unmet medical need. Market entry has been supported by regulatory approvals in key regions, including the U.S. (July 2021) and EU (August 2021). Price projections for KERENDIA are influenced by its novel therapeutic approach, clinical trial data demonstrating improved renal and cardiovascular outcomes, and the competitive landscape. The U.S. list price is approximately $13,200 annually per patient. Pricing strategies are expected to balance market access with recouping R&D investments and reflecting the drug's value proposition in reducing disease progression and associated healthcare costs.

What is KERENDIA and its Therapeutic Target?

KERENDIA is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist. Its primary therapeutic target is the reduction of CKD progression and cardiovascular events in adults with T2D. The MR plays a role in inflammation and fibrosis, pathways implicated in the pathophysiology of diabetic kidney disease. By blocking the MR, finerenone aims to mitigate these detrimental effects, thereby preserving kidney function and reducing cardiovascular risk.

The drug is approved for:

• Diabetic Kidney Disease (CKD) with Type 2 Diabetes: Specifically indicated for patients with established T2D and diabetic kidney disease, evidenced by albuminuria.

Key clinical trials supporting its approval include:

• FIDELIO-DKD: Demonstrated a reduction in the composite outcome of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, or renal death in patients with T2D and CKD.
• FIGARO-DKD: Showed a reduction in the composite outcome of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke in patients with T2D and CKD.

These trials have established finerenone's ability to improve renal and cardiovascular outcomes in a patient population with significant unmet needs.

What is the Global Market Size and Growth Potential for KERENDIA?

The global market for CKD treatments, particularly for patients with T2D, is substantial and projected to grow. This growth is driven by the increasing prevalence of T2D and its complications, including diabetic kidney disease. KERENDIA's novel mechanism of action and demonstrated efficacy in reducing both renal and cardiovascular events position it to capture a significant share of this market.

Market Size Drivers:

• High Prevalence of T2D and CKD: Globally, hundreds of millions of individuals have T2D, and a significant proportion develop CKD. In the U.S. alone, over 37 million people have diabetes, and kidney disease is a common complication (1).
• Unmet Medical Need: Before KERENDIA, treatment options for slowing CKD progression in T2D patients were limited, often relying on ACE inhibitors and ARBs, which do not fully address the underlying MR pathway.
• Clinical Trial Efficacy: The positive results from FIDELIO-DKD and FIGARO-DKD trials provide strong clinical evidence for KERENDIA's benefit, supporting physician adoption and patient access.
• Aging Population: The global aging population contributes to an increased incidence of chronic diseases, including T2D and CKD.

Market Growth Projections (Estimates):

While precise market size figures for KERENDIA are proprietary and subject to dynamic market conditions, analysts project a significant uptake.

• Projected Market Share: Reports indicate that finerenone could achieve peak annual sales exceeding $5 billion globally, driven by its broad indication for T2D-associated CKD (2).
• Compound Annual Growth Rate (CAGR): The overall CKD market is expected to grow at a CAGR of approximately 5-7% over the next decade, with novel therapies like KERENDIA expected to outpace this average in its initial years.

The market growth is contingent on factors such as physician education, formulary access, patient adherence, and the emergence of competing therapies.

What are the Key Regulatory Approvals and Geographic Market Entry for KERENDIA?

Regulatory approvals are critical milestones for drug market entry and commercialization. KERENDIA has secured approvals in major pharmaceutical markets, enabling its global rollout.

Key Regulatory Milestones:

• United States (U.S. Food and Drug Administration - FDA):
  • Approval Date: July 8, 2021
  • Indication: For the treatment of chronic kidney disease (CKD) with type 2 diabetes (T2D) in adults (3).
• European Union (European Medicines Agency - EMA):
  • Approval Date: August 24, 2021
  • Indication: For the treatment of chronic kidney disease (CKD) in adult patients with type 2 diabetes (T2D) (4).
• Other Key Markets: Approvals have also been obtained in other significant markets, including Japan, Canada, and Australia, facilitating broader patient access.

Geographic Market Entry Strategy:

Bayer's market entry strategy typically involves a phased approach, prioritizing regions with high disease burden, established healthcare infrastructure, and favorable reimbursement landscapes.

• North America (U.S. and Canada): Early market entry with a focus on demonstrating value through clinical outcomes and cost-effectiveness data.
• Europe: Leveraging existing relationships with national health systems and payers to secure market access and reimbursement.
• Asia-Pacific (including Japan): Targeting markets with a growing prevalence of T2D and CKD, adapting market access strategies to local healthcare systems.
• Emerging Markets: Phased introduction based on market readiness, regulatory pathways, and the ability to provide affordable access.

The timeline for these approvals and subsequent market launches has been crucial in establishing KERENDIA's position in the therapeutic landscape.

What is the Pricing Strategy and Reimbursement Status of KERENDIA?

Pricing and reimbursement are pivotal determinants of a drug's market access and commercial success. KERENDIA's pricing reflects its novel mechanism, clinical trial outcomes, and the value it delivers in managing a chronic, progressive disease.

U.S. Pricing:

• List Price: The U.S. list price for KERENDIA is approximately $13,200 per patient per year. This price is based on a typical daily dosage of 20 mg.
• Net Price: Actual net prices paid by payers are subject to rebates, discounts, and contract negotiations with pharmacy benefit managers (PBMs) and insurance providers.

European Pricing:

• Varied Pricing: Pricing in European countries is subject to national negotiation and health technology assessment (HTA) processes. Prices vary significantly by country.
• Health Technology Assessment (HTA): KERENDIA undergoes HTA reviews in various European countries to determine its cost-effectiveness and value for money relative to existing treatments.

Reimbursement Status:

• U.S.:
  • Medicare and Medicaid: Coverage is available for eligible beneficiaries, subject to formulary placement and utilization management.
  • Commercial Insurers: Coverage varies by plan. Manufacturers actively engage with commercial payers to ensure formulary inclusion.
  • Patient Assistance Programs: Bayer offers patient assistance programs to help eligible patients with financial burdens, enhancing access.
• Europe:
  • National Health Systems: Reimbursement decisions are made at the national level, often involving the submission of pharmacoeconomic data.
  • Formulary Placement: Securing inclusion on national and regional formularies is a key step for market access.

Pricing Justification:

Bayer positions KERENDIA's price based on:

• Disease Burden: The significant morbidity, mortality, and healthcare costs associated with CKD and T2D.
• Clinical Value: The demonstrated reduction in kidney disease progression (eGFR decline) and cardiovascular events.
• Reduced Healthcare Costs: The potential for KERENDIA to offset higher costs associated with end-stage renal disease (ESRD), dialysis, kidney transplantation, and cardiovascular events.
• Novelty: The unique non-steroidal MR antagonist mechanism of action.

The pricing strategy aims to balance market penetration with the need to recoup significant R&D investments and achieve profitability.

What is the Competitive Landscape for KERENDIA?

The market for CKD treatments in T2D is evolving, with several established and emerging therapeutic classes. KERENDIA's competitive positioning is defined by its unique mechanism of action and demonstrated outcomes.

Current Treatment Landscape:

• Standard of Care:
  • Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARBs): These are foundational therapies for managing hypertension and proteinuria in diabetic kidney disease. However, they do not fully address the underlying MR-driven inflammation and fibrosis.
  • Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Drugs like empagliflozin, dapagliflozin, and canagliflozin have shown significant renal and cardiovascular benefits in patients with T2D and CKD. They represent a major competitive class.
  • Statins: For managing cardiovascular risk factors.
  • Glycemic Control Agents: Management of blood glucose remains critical.

Key Competitors and Competitive Dynamics:

1. SGLT2 Inhibitors (e.g., Jardiance, Farxiga, Invokana):

   • Mechanism: Inhibit glucose reabsorption in the kidneys, leading to glycosuria and also having direct renoprotective and cardioprotective effects independent of glucose lowering.
   • Competitive Advantage: Broad use in T2D and established efficacy in reducing CKD progression and cardiovascular events. Many are now approved for heart failure with reduced ejection fraction (HFrEF) and CKD without diabetes.
   • KERENDIA's Differentiator: KERENDIA targets the MR pathway, complementing the effects of SGLT2 inhibitors. Clinical trials are exploring combination therapy.

2. Newer MR Antagonists (under development):

   • Pipeline: Other non-steroidal MR antagonists are in various stages of clinical development. These could pose future competition.
   • KERENDIA's Advantage: First-mover advantage in the non-steroidal MR antagonist class for diabetic kidney disease.

3. Endothelin Receptor Antagonists (ERAs) (e.g., atrasentan):

   • Mechanism: Block the action of endothelin-1, a vasoconstrictor implicated in kidney damage.
   • Status: Atrasentan has shown positive results in clinical trials for specific patient populations with CKD.
   • KERENDIA's Position: Targets a different pathway, offering potential for combination therapy.

KERENDIA's Competitive Positioning:

• Unique Mechanism: Its MR antagonism provides a distinct therapeutic approach, addressing inflammatory and fibrotic pathways not fully targeted by SGLT2 inhibitors or other classes.
• Dual Benefit: Demonstrated efficacy in both renal and cardiovascular outcomes is a strong value proposition.
• Complementary Therapy: KERENDIA is increasingly viewed as a complementary therapy to SGLT2 inhibitors, creating opportunities for combination use that could improve overall patient outcomes. Bayer is actively investigating such combinations.
• Patient Population: Targets a broad population of adults with T2D and CKD, with the potential to expand to CKD patients without diabetes if further trials are successful.

The competitive landscape necessitates clear value communication, robust clinical data, and strategic market access initiatives to ensure KERENDIA's sustained market penetration.

What are the Projected Future Market Trends and Price Elasticity for KERENDIA?

The future market trajectory of KERENDIA will be shaped by evolving treatment paradigms, clinical data, and economic factors. Price elasticity will play a role in how readily the market adopts the drug at its current price point and potential future adjustments.

Future Market Trends:

1. Combination Therapy: The most significant trend will likely be the increased use of KERENDIA in combination with SGLT2 inhibitors.

   • Rationale: Clinical trials are exploring the synergistic benefits of targeting both the MR and SGLT2 pathways to achieve greater renoprotection and cardiovascular risk reduction than monotherapy.
   • Market Impact: This could lead to expanded use and potentially higher overall treatment costs per patient, but with improved outcomes and reduced long-term healthcare expenditures.

2. Expansion to Broader CKD Populations:

   • CKD without Diabetes: Bayer has initiated trials (e.g., CONFIDENCE) to evaluate finerenone in patients with CKD without diabetes. Positive results could significantly expand the drug's addressable market.
   • Earlier Stage CKD: Further research may explore the benefit of finerenone in earlier stages of CKD.

3. Increased Competition:

   • Pipeline Drugs: The emergence of other novel agents targeting different pathways in CKD (e.g., novel ERAs, anti-fibrotic agents) will intensify competition.
   • Generics: The long-term competitive threat of generic erosion will emerge after patent expiry.

4. Value-Based Healthcare and Outcomes-Based Agreements:

   • Payer Pressure: Payers are increasingly demanding evidence of real-world effectiveness and cost savings.
   • Negotiation: Expect more sophisticated pricing and reimbursement models, including outcomes-based agreements where payment is linked to patient benefits.

5. Focus on Patient Adherence and Real-World Evidence:

   • Long-term Outcomes: Generating robust real-world evidence will be crucial to support long-term adherence and demonstrate sustained value beyond clinical trial data.

Price Elasticity:

Price elasticity refers to the responsiveness of demand to changes in price. For pharmaceuticals, especially innovative treatments for serious conditions, demand is generally considered inelastic, meaning demand changes less than proportionally to price changes, particularly when there are limited alternatives.

• Inelastic Demand: KERENDIA's target indication addresses a significant unmet need with limited alternatives offering its specific mechanism. This suggests that demand is likely to be relatively inelastic, especially in the initial years of its market exclusivity. Patients with progressive CKD and their physicians are likely to prioritize effective treatments even at a high cost if insurance covers it.
• Factors Influencing Elasticity:
  • Availability of Substitutes: The availability and efficacy of SGLT2 inhibitors and potential future therapies will influence price elasticity. If SGLT2 inhibitors demonstrate comparable or superior overall value (including cost), demand for KERENDIA could become more elastic.
  • Insurance Coverage and Co-pays: High co-pays or limited insurance coverage would increase price sensitivity and make demand more elastic. Conversely, broad formulary access and patient assistance programs reduce price sensitivity.
  • Demonstrated Clinical and Economic Value: Strong evidence of superior clinical outcomes and cost savings (e.g., reduction in dialysis, hospitalizations) justifies higher prices and reduces elasticity.
  • Physician Prescribing Habits: Physician acceptance and prescribing patterns, influenced by clinical trial data and formulary status, will impact demand.

Price Projections:

• Short to Medium Term (1-5 years): The list price of KERENDIA is expected to remain relatively stable, reflecting its innovative status and market exclusivity. Net prices may fluctuate based on ongoing payer negotiations and rebate strategies.
• Long Term (Post-Patent Expiry): Once patent protection expires, generic competition would lead to significant price reductions, as is typical for pharmaceutical markets. However, patents for finerenone are complex and may involve multiple layers of protection.
• Potential for Price Adjustments: While unlikely in the short term, price adjustments (upward or downward) could occur based on market uptake, competitor pricing, and payer negotiations. An increase might be justified if superior real-world outcomes are demonstrated or if the drug gains new indications. A decrease could be considered to expand market access in price-sensitive regions or if competition intensifies significantly.

The market for KERENDIA will continue to be dynamic, with its pricing and growth influenced by a complex interplay of clinical innovation, competitive pressures, and evolving healthcare economics.

Key Takeaways

• KERENDIA (finerenone) is approved for treating chronic kidney disease (CKD) associated with type 2 diabetes (T2D), targeting inflammation and fibrosis via mineralocorticoid receptor antagonism.
• The U.S. list price is approximately $13,200 annually per patient, with prices varying in Europe based on national negotiations.
• Regulatory approvals have been secured in key markets, including the U.S. (July 2021) and EU (August 2021).
• The market size for CKD treatments in T2D is substantial and growing, with KERENDIA projected to capture significant sales due to its novel mechanism and dual renal/cardiovascular benefits.
• Key competitors include SGLT2 inhibitors, which have established efficacy; KERENDIA is often viewed as a complementary therapy.
• Future market trends include increased use in combination therapies with SGLT2 inhibitors and potential expansion to CKD patients without diabetes.
• Demand for KERENDIA is expected to be relatively inelastic in the short to medium term due to its unique mechanism and unmet need, though competition and payer access will influence price sensitivity.

Frequently Asked Questions

1. What is the primary mechanism of action for KERENDIA? KERENDIA is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist that inhibits the effects of aldosterone, thereby reducing inflammation and fibrosis in the kidneys.

2. What are the key clinical trials that supported KERENDIA's approval? The FIDELIO-DKD trial demonstrated a reduction in renal composite outcomes, and the FIGARO-DKD trial showed a reduction in cardiovascular composite outcomes.

3. How does KERENDIA compare to SGLT2 inhibitors in treating diabetic kidney disease? SGLT2 inhibitors primarily work by reducing glucose reabsorption in the kidneys, while KERENDIA targets the mineralocorticoid receptor pathway. Both have demonstrated efficacy in slowing CKD progression, and they are often considered complementary therapies.

4. What is the estimated annual cost of KERENDIA in the United States? The U.S. list price for KERENDIA is approximately $13,200 per patient per year.

5. Could KERENDIA be used for patients with CKD but without type 2 diabetes? Bayer is investigating the use of finerenone in patients with CKD without diabetes in ongoing clinical trials, such as the CONFIDENCE study.

Citations

[1] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Diabetes and Chronic Kidney Disease. Retrieved from https://www.niddk.nih.gov/health-information/diabetes/chronic-kidney-disease

[2] Reuters. (2021, July 9). Bayer's new kidney disease drug Kerendia wins U.S. approval. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-kidney-disease-drug-kerendia-wins-us-approval-2021-07-09/

[3] U.S. Food and Drug Administration. (2021, July 9). FDA Approves New Drug to Treat Chronic Kidney Disease Associated with Type 2 Diabetes. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-treat-chronic-kidney-disease-associated-type-2-diabetes

[4] European Medicines Agency. (2021, August 24). European Commission approves KERENDIA® (finerenone) for the treatment of chronic kidney disease associated with type 2 diabetes. Retrieved from https://www.ema.europa.eu/en/news/european-commission-approves-kerendia-finerenone-treatment-chronic-kidney-disease-associated-type-2-diabetes